Bank of Hawaii Sells 155 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Bank of Hawaii reduced its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 1.0% during the third quarter, Holdings Channel.com reports. The fund owned 15,023 shares of the company’s stock after selling 155 shares during the quarter. Bank of Hawaii’s holdings in Vaxcyte were worth $1,717,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PCVX. Riverview Trust Co purchased a new position in shares of Vaxcyte during the third quarter worth about $27,000. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Fifth Third Bancorp purchased a new position in Vaxcyte in the 2nd quarter worth approximately $35,000. J.Safra Asset Management Corp grew its stake in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after buying an additional 526 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its holdings in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PCVX shares. Jefferies Financial Group lifted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. BTIG Research lifted their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Leerink Partners upped their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Bank of America upped their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $147.50.

Vaxcyte Price Performance

NASDAQ PCVX opened at $88.54 on Monday. Vaxcyte, Inc. has a 1-year low of $48.24 and a 1-year high of $121.06. The stock has a 50-day moving average of $107.89 and a 200-day moving average of $89.57.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the company posted ($0.91) earnings per share. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Insider Activity at Vaxcyte

In other Vaxcyte news, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the sale, the senior vice president now owns 28,623 shares in the company, valued at approximately $3,127,635.21. This trade represents a 14.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. This trade represents a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 102,464 shares of company stock worth $11,455,576 in the last three months. 3.10% of the stock is owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.